McKesson Corporation · NYSE (us_market)
Healthcare · Medical Distribution · United States
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products; delivers products to retail pharmacies, hospitals, long-term care centers, clinics, and institutions; and provides logistics and distribution services for manufacturers. It also provides consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies; gene therapy with InspiroGene, practice consulting, and vaccine distribution services; and technology solutions, as well as research, insights, technologies, and services to improve cancer and specialty care. In addition, the company helps in solving medication access, affordability, and adherence challenges for patients by working across healthcare to connect patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies. Further, it offers technology services, which includes electronic prior authorization, prescription price transparency, benefit insight, dispensing support services, patient enrollment, third-party logistics, and wholesale distribution support; medical-surgical supplies, laboratory equipment, pharmaceutical distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, and hospital reference labs, nursing homes, hospice and home health care agencies, government facilities ,and online marketplaces and retailers. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2024-08-02$630.38 RISE2024-09-26$479.06 PEAK2024-11-29$628.50 119d | -24.0% 55d | Missed | Missed | — | — | +31.2% 64d | Missed |
DROP2022-11-03$397.58 RISE2023-03-15$335.35 PEAK2023-05-17$400.96 195d | -15.7% 132d | Missed | Missed | — | — | +19.6% 63d | Missed |
DROP2020-02-21$170.96 RISE2020-05-14$129.42 PEAK2020-06-08$164.68 108d | -24.3% 83d | Missed | Missed | — | — | +27.2% 25d | Missed |
DROP2020-02-21$170.96 RISE2020-03-23$115.75 PEAK2020-06-08$164.68 108d | -32.3% 31d | Missed | Missed | — | — | +42.3% 77d | Missed |
Zacks.com users have recently been watching McKesson (MCK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Get this weekly dividend update on Champions, Contenders & Challengersâsee dividend changes, upcoming ex-dividend dates and pay dates.
Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at McKesson (NYSE:MCK) and its peers.
Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at McKesson (NYSE:MCK) and its peers.
McKesson's oncology growth, GLP-1 momentum and RxTS expansion support earnings strength, but pricing reform and margin pressures pose risks.
McKesson's oncology growth, GLP-1 momentum and RxTS expansion support earnings strength, but pricing reform and margin pressures pose risks.
TruBridge climbs after Q1 EPS beats estimates and an IKS Health buyout deal sets a $26.25-per-share cash offer for shareholders.
TruBridge climbs after Q1 EPS beats estimates and an IKS Health buyout deal sets a $26.25-per-share cash offer for shareholders.
McKesson has underperformed the broader market over the past year, but analysts are highly optimistic about the stock’s prospects.
McKesson has underperformed the broader market over the past year, but analysts are highly optimistic about the stock’s prospects.
BOSTON, May 21, 2026--Ontada®, a business for oncology insights, announced the inclusion of Florida Cancer Specialists & Research Institute's data into its ecosystem.
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.
TCW Funds, an investment management firm, published its first-quarter 2026 investor letter for the ‘TCW Concentrated Large Cap Growth Fund.’ A copy of the letter is available to download here. The first quarter was marked by volatility in equity markets, driven by geopolitical tensions, concerns about the private credit sector, a government shutdown, and ongoing […]
TCW Funds, an investment management firm, published its first-quarter 2026 investor letter for the ‘TCW Concentrated Large Cap Growth Fund.’ A copy of the letter is available to download here. The first quarter was marked by volatility in equity markets, driven by geopolitical tensions, concerns about the private credit sector, a government shutdown, and ongoing […]
Eagle Point Capital, an investment firm, released its “Spring 2026 Portfolio Update” investor letter. A copy of the letter can be downloaded here. The firm reported a resilient performance for the quarter while emphasizing its long-term, fundamentals-driven strategy, noting that detailed quarterly returns would be reflected in client brokerage statements but reaffirming steady compounding aligned […]
Eagle Point Capital, an investment firm, released its “Spring 2026 Portfolio Update” investor letter. A copy of the letter can be downloaded here. The firm reported a resilient performance for the quarter while emphasizing its long-term, fundamentals-driven strategy, noting that detailed quarterly returns would be reflected in client brokerage statements but reaffirming steady compounding aligned […]
Latitude Investment Management, an investment management firm, released its fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. The letter emphasizes a long-term, fundamentals-driven investment philosophy, arguing that while stock prices can be volatile in the short run, they ultimately follow underlying earnings growth—illustrated through the “dog and owner” analogy. The […]
Latitude Investment Management, an investment management firm, released its fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. The letter emphasizes a long-term, fundamentals-driven investment philosophy, arguing that while stock prices can be volatile in the short run, they ultimately follow underlying earnings growth—illustrated through the “dog and owner” analogy. The […]
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| MCK | -8.79% | -25.08% | -9.49% | +3.19% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -11.76% | -19.36% | -6.05% | -9.50% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 5.73M | $4.96B | 0.17% | Trimmed-0.8% | 2026-03-31 |
| FidelityFMR | fundamental | 3.60M | $3.12B | 0.16% | Added+12.4% | 2026-03-31 |
| LonePine | growth | 392.2K | $339.41M | 2.71% | New | 2026-03-31 |
| RenTech | quant | 117.2K | $101.46M | 0.16% | Added+91.3% | 2026-03-31 |
| Bridgewater | macro | 67.4K | $58.31M | 0.26% | Unchanged | 2026-03-31 |
| DEShaw | quant | 53.3K | $46.16M | 0.03% | Trimmed-48.0% | 2026-03-31 |
| Wellington | fundamental | 40.6K | $35.15M | 0.01% | Trimmed-81.2% | 2026-03-31 |
| TwoSigma | quant | 6.2K | $5.36M | 0.00% | Unchanged | 2026-03-31 |
| TRowePrice | fundamental | 794.7K | $687.66K | 0.08% | Trimmed-5.1% | 2026-03-31 |
| Filed | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-27 | Fraga Francisco | EVP, CIO and CTO | M Option exercise(deriv) | 136 | — | +$0 |
| 2026-05-27 | Fraga Francisco | EVP, CIO and CTO | F Tax withholding | 54 | $766.08 | −$41.4K |
| 2026-05-27 | Fraga Francisco | EVP, CIO and CTO | M Option exercise | 136 | — | +$0 |
| 2026-05-27 | Rutledge Napoleon B JR | SVP, Controller & CAO | M Option exercise(deriv) | 136 | — | +$0 |
| 2026-05-27 | Rutledge Napoleon B JR | SVP, Controller & CAO | F Tax withholding | 41 | $766.08 | −$31.4K |
| 2026-05-27 | Rutledge Napoleon B JR | SVP, Controller & CAO | M Option exercise | 136 | — | +$0 |
| 2026-05-27 | Rodgers Thomas L | EVP, Chief Strategy & BDO | M Option exercise(deriv) | 594 | — | +$0 |
| 2026-05-27 | Rodgers Thomas L | EVP, Chief Strategy & BDO | S Open-market sale | 2,388 | $761.09 | −$1.82M |
| 2026-05-27 | Rodgers Thomas L | EVP, Chief Strategy & BDO | F Tax withholding | 234 | $766.08 | −$179.3K |
| 2026-05-27 | Rodgers Thomas L | EVP, Chief Strategy & BDO | M Option exercise | 594 | — | +$0 |
| 2026-05-27 | Smith LeAnn B | EVP & Chief HR Officer | M Option exercise(deriv) | 679 | — | +$0 |
| 2026-05-27 | Smith LeAnn B | EVP & Chief HR Officer | F Tax withholding | 268 | $766.08 | −$205.3K |
| 2026-05-27 | Smith LeAnn B | EVP & Chief HR Officer | M Option exercise | 679 | — | +$0 |
| 2026-05-27 | Vitalone Britt J. | EVP & CFO | M Option exercise(deriv) | 1,476 | — | +$0 |
| 2026-05-27 | Vitalone Britt J. | EVP & CFO | F Tax withholding | 581 | $766.08 | −$445.1K |
| 2026-05-27 | Vitalone Britt J. | EVP & CFO | M Option exercise | 1,476 | — | +$0 |
| 2026-05-27 | TYLER BRIAN S. | Chief Executive Officer | M Option exercise(deriv) | 4,579 | — | +$0 |
| 2026-05-27 | TYLER BRIAN S. | Chief Executive Officer | F Tax withholding | 1,831 | $766.08 | −$1.40M |
| 2026-05-27 | TYLER BRIAN S. | Chief Executive Officer | M Option exercise | 4,579 | — | +$0 |
| 2026-05-27 | Lau Michele | EVP and Chief Legal Officer | S Open-market sale | 3,550 | $761.09 | −$2.70M |
| 2026-05-26 | Fraga Francisco | EVP, CIO and CTO | M Option exercise(deriv) | 483 | — | +$0 |
| 2026-05-26 | Fraga Francisco | EVP, CIO and CTO | F Tax withholding | 191 | $766.50 | −$146.4K |
| 2026-05-26 | Fraga Francisco | EVP, CIO and CTO | M Option exercise | 483 | — | +$0 |
| 2026-05-26 | Lau Michele | EVP and Chief Legal Officer | M Option exercise(deriv) | 724 | — | +$0 |
| 2026-05-26 | Lau Michele | EVP and Chief Legal Officer | F Tax withholding | 285 | $766.50 | −$218.5K |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-05upcoming | 9.58 | — | — |
| 2026-05-07 | 11.57 | 11.69 | +1.06% |
| 2026-02-04 | 9.27 | 9.34 | +0.71% |
| 2025-11-05 | 9.05 | 9.86 | +8.94% |
| 2025-08-06 | 8.15 | 8.26 | +1.39% |
| 2025-05-08 | 9.83 | 10.12 | +2.98% |
| 2025-02-05 | 7.99 | 8.03 | +0.47% |
| 2024-11-06 | 6.87 | 7.07 | +2.90% |
| 2024-08-07 | 7.21 | 7.88 | +9.30% |
| 2024-05-07 | 6.36 | 6.18 | -2.77% |
| 2024-02-07 | 7.05 | 7.74 | +9.79% |
| 2023-11-01 | 6.15 | 6.23 | +1.33% |
| 2023-08-02 | 5.87 | 7.27 | +23.89% |
| 2023-05-08 | 7.12 | 7.19 | +0.93% |
| 2023-02-01 | 6.36 | 6.90 | +8.45% |
| 2022-11-01 | 6.10 | 6.06 | -0.65% |